This database contains 59 studies, archived under the term: "efficacy"
Click here to filter this large number of results.
The Tailored Activity Program to reduce behavioral symptoms in individuals with dementia: feasibility, acceptability, and replication potential
Gitlin, Laura N,
Winter, Laraine,
Vause Earland, Tracey,
Adel Herge, E.,
Chernett, Nancy L.,
Piersol, Catherine V.,
Burke, Janice P.
Purpose: The Tailored Activity Program (TAP) is a home-based occupational therapy intervention shown to reduce behavioral symptoms and caregiver burden in a randomized trial. This article describes TAP, its assessments, acceptability, and replication potential.; Design and Methods: TAP involves 8 sessions for a period of 4 months. Interventionists identify preserved capabilities, previous roles, habits, and […]
Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease
Gehrman, Philip R.,
Connor, Donald J.,
Martin, Jennifer L.,
Shochat, Tamar,
Corey-Bloom, Jody,
Ancoli-Israel, Sonia
Objectives: Patients with Alzheimer dementia often display both agitated behavior and poor sleep. Given that the disease is often associated with low endogenous levels of melatonin, exogenous melatonin administration may lead to improvements in sleep and agitation.; Design: Randomized, placebo-controlled study.; Setting: Nursing homes in San Diego, CA, metropolitan area.; Participants: Subjects were patients with […]
Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study
Gold, Michael,
Alderton, Claire,
Zvartau-Hind, Marina,
Egginton, Sally,
Saunders, Ann M.,
Irizarry, Michael,
Craft, Suzanne,
Landreth, Gary,
Linnamägi, Ulla,
Sawchak, Sharon
Background/aims: A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer’s disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-ε4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate […]
Efficacy of akatinol memantine in moderate cognitive impairments
A six-month open clinical trial of the efficacy of Akatinol was conducted in 40 patients with moderate cognitive impairments (MCI) using piracetam (20 patients) as reference agent; mean age was 67.7 +/- 7.2 years. Patient status was evaluated using a number of scales, questionnaires, and neuropsychological tests prior to treatment and at three and six […]
A telephone intervention for dementia caregivers: background, design, and baseline characteristics
Tremont, Geoffrey,
Davis, Jennifer,
Papandonatos, George D.,
Grover, Christine,
Ott, Brian R.,
Fortinsky, Richard H.,
Gozalo, Pedro,
Bishop, Duane S.
Family caregivers of individuals with dementia are at heightened risk for emotional and mental health problems. Many caregivers do not seek assistance or become isolated in their caregiving role. Multi-component interventions have demonstrated efficacy for reducing emotional distress and burden, although these approaches are potentially costly and are not widely accessible. In response to these […]
Improving psychotropic drug prescription in nursing home patients with dementia: design of a cluster randomized controlled trial
Smeets, Claudia H. W.,
Smalbrugge, Martin,
Gerritsen, Debby L,
Nelissen-Vrancken, Marjorie H. J. M. G.,
Wetzels, Roland B.,
van der Spek, Klaas,
Zuidema, Sytse U.,
Koopmans, Raymond T. C. M.
Background: Neuropsychiatric symptoms are highly prevalent in nursing home patients with dementia. Despite modest effectiveness and considerable side effects, psychotropic drugs are frequently prescribed for these neuropsychiatric symptoms. This raises questions whether psychotropic drugs are appropriately prescribed. The aim of the PROPER (PRescription Optimization of Psychotropic drugs in Elderly nuRsing home patients with dementia) II […]
Dementia care management: going new ways in ambulant dementia care within a GP-based randomized controlled intervention trial
Eichler, Tilly,
Thyrian, Jochen René,
Dreier, Adina,
Wucherer, Diana,
Kohler, Leonore,
Fiß, Thomas,
Böwing, Georgia,
Michalowsky, Bernhard,
Hoffmann, Wolfgang
Background: Increasing prevalence of dementia is a major challenge for the German healthcare system. The study DelpHi-MV (“Dementia: life- and person-centered help in Mecklenburg-Western Pomerania”) aims to implement and evaluate an innovative subsidiary support system for persons with dementia (PwDs) living at home and their caregivers.; Methods: DelpHi-MV is a GP-based cluster randomized controlled intervention […]
Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer’s Disease: the MEMAGE study
Gareri, Pietro,
Putignano, Daria,
Castagna, Alberto,
Cotroneo, Antonino Maria,
De Palo, Grazia,
Fabbo, Andrea,
Forgione, Luigi,
Giacummo, Attilio,
Lacava, Roberto,
Marino, Saverio,
Simone, Maurizio,
Zurlo, Amedeo,
Putignano, Salvatore
Background: Combined therapy of memantine and acetylcholinesterase inhibitors (AChEIs) in patients with Alzheimer’s disease (AD) may be associated with higher benefits than either monotherapy.; Objective: This retrospective multicentric study conducted in seven Italian Ambulatory Centers for Dementia assessed the efficacy and safety of memantine 20 mg/day administered for 6 months in addition to an AChEI […]
Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer’s Disease Study 2
Flynn Longmire, Crystal V.,
Drye, Lea T.,
Frangakis, Constantine E.,
Martin, Barbara K.,
Meinert, Curtis L.,
Mintzer, Jacobo E.,
Munro, Cynthia A.,
Porsteinsson, Anton P.,
Rabins, Peter V.,
Rosenberg, Paul B.,
Schneider, Lon S.,
Weintraub, Daniel,
Lyketsos, Constantine G.
Objective: We wanted to assess if sertraline treatment (versus placebo) or remission of depression at 12 weeks (versus nonremission) in Alzheimer patients is associated with improved caregiver well being.; Methods: We conducted a randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of sertraline for the treatment of depression in individuals with Alzheimer disease […]
Comparing the efficacy and safety of Crocus sativus L. With memantine in patients with moderate to severe Alzheimer’s disease: A double‐blind randomized clinical trial
Farokhnia, Mehdi,
Shafiee Sabet, Mehdi,
Iranpour, Negar,
Gougol, Amirhossein,
Yekehtaz, Habibeh,
Alimardani, Roozbeh,
Farsad, Farzaneh,
Kamalipour, Maryam,
Akhondzadeh, Shahin
Objectives Limited pharmacological options are available for the management of Alzheimer’s disease (AD) in severe stages. Cognitive‐enhancing properties of saffron, the dried stigma of Crocus sativus L., have been evidenced in different studies. We aimed to compare the efficacy and safety of saffron extract versus memantine in reducing cognitive deterioration of patients with moderate to […]